The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
How Much Larger Will The Minimal Residual Disease Testing Market Become By 2030 Compared To 2026?
The minimal residual disease testing market has experienced rapid expansion in recent years. It is projected to increase from $1.8 billion in 2025 to $2.02 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 12.5%. The historical growth of this market can be linked to factors such as the increasing prevalence of hematological malignancies, ongoing advancements in molecular diagnostic technologies, greater awareness regarding minimal residual disease, the rising adoption of precision medicine, and supportive government healthcare programs.
The minimal residual disease testing market is projected for substantial expansion in the coming years, with its valuation set to reach $3.31 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 13.1%. This growth during the forecast period can be linked to several factors, including advancements in technologies like nGS and digital PCR, increased funding for cancer research, a rise in collaborations between diagnostic and pharmaceutical firms, a greater need for personalized treatment monitoring, and improvements in healthcare infrastructure within emerging markets. Key trends anticipated for this period encompass the adoption of liquid biopsy, enhanced personalized cancer monitoring, improvements in early detection and prognosis, the integration of molecular diagnostics, and an expansion in oncology research.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9970&type=smp
Which Major Factors Are Contributing To The Development Of The Minimal Residual Disease Testing Market?
The rising occurrence of cancer is projected to fuel expansion within the minimal residual disease testing market in the future. Cancer is defined as a state where some cells in the body multiply uncontrollably and disseminate to other parts. Minimal residual disease testing, a highly sensitive technique for identifying cancer cells in humans, serves as the main method for detecting cancer stages. This method aids cancer patients in early disease prevention, thereby enhancing the minimal residual disease testing market. For example, data from January 2023, provided by the U.S.-based government agency, the National Institutes of Health (NIH), indicated that in 2023, the United States recorded 1,958,310 new cancer cases and 609,820 cancer deaths. Consequently, the growing frequency of cancer is a key factor propelling the expansion of the minimal residual disease testing market.
Which Segment Divisions Form The Structure Of The Minimal Residual Disease Testing Market?
The minimal residual disease testing market covered in this report is segmented –
1) By Test Type: DNA – Based Test, RNA- Based Test, Immunological Test
2) By Technology: Flow Cytometry, Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Other Technologies
3) By Application: Hematological Malignancies, Leukemia, Lymphoma, Solid Tumors, Other Application
4) By End User: Hospitals And Specialty Clinics, Diagnostic Laboratories, Academic And Research Institutes, Other End Users
Subsegments:
1) By DNA-Based Test: Polymerase Chain Reaction (PCR) Tests, Next-Generation Sequencing (NGS), Digital PCR
2) By RNA-Based Test: Reverse Transcription PCR (RT-PCR), RNA Sequencing, Quantitative PCR (qPCR)
3) By Immunological Test: Flow Cytometry, Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry
What Trends Are Influencing The Minimal Residual Disease Testing Market Outlook?
Leading companies within the minimal residual disease testing market are introducing cancer research diagnostic solutions to bolster detection accuracy, refine treatment monitoring, and advance personalized medicine strategies, aiming for improved patient outcomes. The IDT Archer FUSIONPlex Core Solid Tumor Panel is a targeted next-generation sequencing assay designed for identifying gene fusions and mutations in solid tumors, contributing to precision oncology and informing treatment decisions. As an illustration, in April 2023, Integrated DNA Technologies (IDT), a US-based provider of genomic solutions, released the IDT Archer FUSIONPlex Core Solid Tumor Panel, an improved cancer research testing solution that now features expanded and optimized coverage for single nucleotide variants (SNVs) and indels. This RNA-based sequencing assay simplifies fusion detection and variant calling in solid tumors, requiring a single sample input and providing researchers with a scalable, user-friendly tool that conserves time, resources, and expenses.
Who Are The Major Companies Operating In The Minimal Residual Disease Testing Market?
Major companies operating in the minimal residual disease testing market are Natera Inc., Guardant Health Inc., Laboratory Corporation of America Holdings, QIAGEN NV, F. Hoffmann-La Roche Ltd., Bio-Techne Corporation, Bio-Rad Laboratories Inc., Sysmex Corporation, Exact Sciences Corporation, GRAIL LLC, Veracyte Inc., Cergentis B.V, Mdxhealth SA, NeoGenomics Laboratories Inc., Adaptive Biotechnologies, Thermo Fisher Scientific Inc., Siemens Healthineers AG, PerkinElmer Inc., Agilent Technologies Inc., ArcherDx Inc., Asuragen Inc., Becton Dickinson and Company, Cepheid Inc., Fluidigm Corporation, Illumina Inc., Invitae Corporation, Luminex Corporation, Menarini Silicon Biosystems S.p.A.
Access The Complete Minimal Residual Disease Testing Market Report:
Which Region Has The Strongest Presence In The Minimal Residual Disease Testing Market?
North America was the largest region in the minimal residual disease testing market in 2025. The regions covered in the minimal residual disease testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Minimal Residual Disease Testing Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample.aspx?id=9970&type=smp
Browse Through More Reports Similar to the Global Minimal Residual Disease Testing Market 2026, By The Business Research Company
Minimal Residual Disease Testing Market Report 2026
Rare Disease Diagnostics Market Report 2026
https://www.thebusinessresearchcompany.com/report/rare-disease-diagnostics-global-market-report
Infectious Disease Diagnostics Testing Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model